These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29472691)

  • 21. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
    Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
    Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.
    Fransen MF; van der Sluis TC; Ossendorp F; Arens R; Melief CJ
    Clin Cancer Res; 2013 Oct; 19(19):5381-9. PubMed ID: 23788581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-7/αIL-7 mAb M25 immunocomplexes expand CD8
    Hrabos D; Hnizdilova T; Tomala J; Uhlik J; Kovar M
    Cytokine; 2020 Sep; 133():155174. PubMed ID: 32599539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
    Brunner-Weinzierl MC; Rudd CE
    Front Immunol; 2018; 9():2737. PubMed ID: 30542345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
    Perez-Ruiz E; Minute L; Otano I; Alvarez M; Ochoa MC; Belsue V; de Andrea C; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Llacer C; Alvarez M; de Luque V; Molina C; Teijeira A; Berraondo P; Melero I
    Nature; 2019 May; 569(7756):428-432. PubMed ID: 31043740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing the Generation of Eomes
    Emerson DA; Rolig AS; Redmond WL
    Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
    Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
    Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
    Ramagopal UA; Liu W; Garrett-Thomson SC; Bonanno JB; Yan Q; Srinivasan M; Wong SC; Bell A; Mankikar S; Rangan VS; Deshpande S; Korman AJ; Almo SC
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4223-E4232. PubMed ID: 28484017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage
    Duperret EK; Trautz A; Stoltz R; Patel A; Wise MC; Perales-Puchalt A; Smith T; Broderick KE; Masteller E; Kim JJ; Humeau L; Muthumani K; Weiner DB
    Cancer Res; 2018 Nov; 78(22):6363-6370. PubMed ID: 30287678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
    Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
    Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
    Callahan MK; Wolchok JD
    J Leukoc Biol; 2013 Jul; 94(1):41-53. PubMed ID: 23667165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-dependent effect of anti-CTLA-4 on survival in sepsis.
    Inoue S; Bo L; Bian J; Unsinger J; Chang K; Hotchkiss RS
    Shock; 2011 Jul; 36(1):38-44. PubMed ID: 21368717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
    Kim EY; Lee EN; Lee J; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Joh JW; Kim SJ
    Exp Mol Med; 2006 Jun; 38(3):284-94. PubMed ID: 16819287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
    Miao G; Sun X
    Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.
    Goswami S; Apostolou I; Zhang J; Skepner J; Anandhan S; Zhang X; Xiong L; Trojer P; Aparicio A; Subudhi SK; Allison JP; Zhao H; Sharma P
    J Clin Invest; 2018 Aug; 128(9):3813-3818. PubMed ID: 29905573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.